High-dose chemotherapy with autologous stem cell rescue in the outpatient setting.
Intensive outpatient care is rapidly becoming the primary mode of care for selected patients undergoing high-dose chemotherapy with autologous peripheral blood stem cell (PBSC) transplantation. Although the traditional inpatient model of care may still be necessary for high-risk patients, published data suggest that outpatient care is safe and feasible during or after administration of high-dose chemotherapy and autologous PBSC transplant. Blood and marrow transplant (BMT) centers have developed programs to provide more outpatient care under three basic models: an early discharge model, a delayed admission model, and a comprehensive, or total, outpatient model. This review will describe these models of care and address the elements necessary for the development of an outpatient BMT program, including patient selection, staff development, and patient and caregiver education. Available supportive care strategies to facilitate outpatient care will also be highlighted. Clinical outcome data and pharmacoeconomic analyses evaluating various outpatient BMT programs, as well as limited quality-of-life evaluations, will be reviewed.
Dix
S P
SP
Blood and Marrow Transplant Program, Saint Luke's Hospital, Kansas City, Missouri, USA.
Geller
R B
RB
D000553:Ambulatory Care / Q000191:economics / Q000458:organization & administration; D000932:Antiemetics / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D003131:Combined Modality Therapy; D003365:Costs and Cost Analysis; D016527:Drug Costs; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics; D006801:Humans; D009369:Neoplasms / Q000191:economics / Q000628:therapy; D009503:Neutropenia / Q000139:chemically induced / Q000628:therapy; D018579:Patient Selection
D000932:Antiemetics